Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -27.20% is 51% below its 5-year average of -18.03%, around the middle of its 5-year range (-63.01%–13.68%).
As of the fiscal period ended Tuesday, June 30, 2026. 144.43% below its 12-month average of -11.13%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -27.20%.
RETURN ON EQUITY (ROE)
-27.20%
RETURN ON EQUITY (ROE) AVG TTM
-11.13%
RETURN ON EQUITY (ROE) AVG 3Y
-21.76%
RETURN ON EQUITY (ROE) AVG 5Y
-18.03%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-144.43%
CURRENT VS 3Y AVG
-25.00%
CURRENT VS 5Y AVG
-50.86%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+35.25%
vs the sector median at left
908 Devices Inc.
Market Cap
$506.12M
Return on Equity (ROE)
-27.20%
TTM Avg
-11.13%
3Y Avg
-21.76%
5Y Avg
-18.03%
Market Cap
$503.93M
Return on Equity (ROE)
-37.94%
TTM Avg
-63.13%
3Y Avg
-60.30%
5Y Avg
-47.34%
Market Cap
$511.84M
Return on Equity (ROE)
-99.83%
TTM Avg
118.83%
3Y Avg
8.21%
5Y Avg
-14.12%
Market Cap
$499.51M
Return on Equity (ROE)
11.11%
TTM Avg
8.28%
3Y Avg
4.14%
5Y Avg
1.14%
Market Cap
$511.87M
Return on Equity (ROE)
-60.79%
TTM Avg
-73.94%
3Y Avg
-62.04%
5Y Avg
-71.62%
Market Cap
$516.48M
Return on Equity (ROE)
N/A
TTM Avg
44.05%
3Y Avg
44.05%
5Y Avg
44.05%
Market Cap
$493.07M
Return on Equity (ROE)
-36.79%
TTM Avg
-82.52%
3Y Avg
-55.07%
5Y Avg
-25.96%
Market Cap
$519.19M
Return on Equity (ROE)
-19.35%
TTM Avg
-58.07%
3Y Avg
-51.86%
5Y Avg
-46.32%
Market Cap
$522.80M
Return on Equity (ROE)
-17.44%
TTM Avg
-97.25%
3Y Avg
-87.77%
5Y Avg
-77.06%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 908 Devices Inc. (MASS) | $506.12M | -27.20% | -11.13% | -21.76% | -18.03% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $503.93M | -37.94% | -63.13% | -60.30% | -47.34% |
| Crescent Biopharma, Inc. (CBIO)vs › | $511.84M | -99.83% | 118.83% | 8.21% | -14.12% |
| Tactile Systems Technology, Inc. (TCMD)vs › | $499.51M | 11.11% | 8.28% | 4.14% | 1.14% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $511.87M | -60.79% | -73.94% | -62.04% | -71.62% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $516.48M | N/A | 44.05% | 44.05% | 44.05% |
| Oculis Holding AG (OCS)vs › | $493.07M | -36.79% | -82.52% | -55.07% | -25.96% |
| Altimmune, Inc. (ALT)vs › | $519.19M | -19.35% | -58.07% | -51.86% | -46.32% |
| Immix Biopharma, Inc. (IMMX)vs › | $522.80M | -17.44% | -97.25% | -87.77% | -77.06% |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.34M | 19.28% | 28.37% | 24.29% | 382.68% |
ROE
-27.2%
ROA
-17.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -27.20% |
| 2026-03-31 | -26.75% |
| 2025-12-31 | 13.68% |
| 2025-09-30 | -2.98% |
| 2025-06-30 | -12.39% |
| 2025-03-31 | -11.09% |
| 2024-12-31 | -63.01% |
| 2024-09-30 | -45.93% |
| 2024-06-30 | -24.29% |
| 2024-03-31 | -22.17% |
| 2023-12-31 | -22.00% |
| 2023-09-30 | -22.81% |
| 2023-06-30 | -21.74% |
| 2023-03-31 | -20.31% |
| 2022-12-31 | -17.61% |
| 2022-09-30 | -13.86% |
| 2022-06-30 | -13.01% |
| 2022-03-31 | -12.33% |
| 2021-12-31 | -10.33% |
| 2021-09-30 | -23.56% |
| 2021-06-30 | -20.11% |
| 2021-03-31 | -11.96% |
| 2020-12-31 | -9.22% |
| 2020-09-30 | -49.41% |
| 2020-06-30 | -80.38% |
| 2020-03-31 | -144.86% |
